Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Irma Bagdoniene: Statin Intolerance – Challenges and Solutions
Irma Bagdoniene/LinkedIn
Feb 1, 2026, 11:48

Irma Bagdoniene: Statin Intolerance – Challenges and Solutions

Irma Bagdoniene, Cardiologist Specializing in Prevention & Lipidology, shared on LinkedIn:

“Statin intolerance: a frequent clinical challenge, but far from a dead end.

True, confirmed statin intolerance with myopathy and CK elevation occurs in about 5% of patients reporting symptoms. Many are actually experiencing the well-documented nocebo effect.

For us, this does not mean stopping therapy. It means adapting our approach.

Most patients labeled ‘intolerant’ do well after switching to another statin (for example, hydrophilic rosuvastatin) or trying low-dose, alternate-day dosing.

For those truly intolerant, therapeutic options remain robust and effective:

• Ezetimibe lowers LDL-C by 15–20%

• Bempedoic acid reduces LDL-C by 15–25% without muscle-related symptoms

• PCSK9 inhibitors provide a powerful 50–60% LDL-C reduction

• Inclisiran, with just twice-yearly dosing, delivers sustained ~60% LDL-C lowering

The CLEAR-Outcomes trial also highlighted that in statin-intolerant patients, hsCRP may predict cardiovascular risk even better than LDL-C.

The take-home message: stopping lipid-lowering therapy should be avoided wherever possible. Re-challenge, switch agents, or refer to a lipid specialist — but never leave high-risk patients unprotected. •

A highly recommended statement on this from the National Lipid Association.”

Irma Bagdoniene: Statin Intolerance - Challenges and Solutions

Stay with Hemostasis Today to explore more from Irma Bagdoniene.

Bempedoic Acid ezetimibe Health Hemostais Hemostasis Today inclisiran Irma Bagdoniene Lipid-Lowering Medications Statin intolerance Statin Therapy thrombosis
NewsFeed